Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
Condition: Angiosarcoma Interventions: Drug: Paclitaxel; Biological: mRNA plus Lysate-loaded Dendritic Cell Vaccine; Drug: PEGYLATED-INTERFERON ALPHA-2A; Drug: Filgrastim Sponsors: M.D. Anderson Cancer Center; Cancer Cures 4 Kids Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Angiosarcoma | Cancer & Oncology | Children | Filgrastim | Immunotherapy | Neulasta | Neupogen | Research | Study | Vaccines